JP2022506956A5 - - Google Patents
Info
- Publication number
- JP2022506956A5 JP2022506956A5 JP2021525115A JP2021525115A JP2022506956A5 JP 2022506956 A5 JP2022506956 A5 JP 2022506956A5 JP 2021525115 A JP2021525115 A JP 2021525115A JP 2021525115 A JP2021525115 A JP 2021525115A JP 2022506956 A5 JP2022506956 A5 JP 2022506956A5
- Authority
- JP
- Japan
- Prior art keywords
- lipid nanoparticles
- nanoparticles according
- approximately
- nucleic acids
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862758088P | 2018-11-09 | 2018-11-09 | |
| US62/758,088 | 2018-11-09 | ||
| PCT/US2019/060582 WO2020097540A1 (en) | 2018-11-09 | 2019-11-08 | Lipid nanoparticle formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022506956A JP2022506956A (ja) | 2022-01-17 |
| JP2022506956A5 true JP2022506956A5 (enExample) | 2022-11-07 |
Family
ID=70611206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021525115A Pending JP2022506956A (ja) | 2018-11-09 | 2019-11-08 | 脂質ナノ粒子製剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12251470B2 (enExample) |
| EP (1) | EP3877521A4 (enExample) |
| JP (1) | JP2022506956A (enExample) |
| KR (1) | KR20210105889A (enExample) |
| CN (1) | CN113286882A (enExample) |
| AU (1) | AU2019376161B2 (enExample) |
| BR (1) | BR112021008982A2 (enExample) |
| EA (1) | EA202191313A1 (enExample) |
| IL (1) | IL282995B1 (enExample) |
| MX (1) | MX2021005389A (enExample) |
| SG (1) | SG11202104807YA (enExample) |
| UA (1) | UA130104C2 (enExample) |
| WO (1) | WO2020097540A1 (enExample) |
| ZA (1) | ZA202103233B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3118559A1 (en) * | 2018-11-09 | 2020-05-14 | Arbutus Biopharma Corporation | Lipid nanoparticle formulations |
| EP4048807A1 (en) | 2019-09-23 | 2022-08-31 | Omega Therapeutics, Inc. | Compositions and methods for modulating apolipoprotein b (apob) gene expression |
| CN114729376A (zh) | 2019-09-23 | 2022-07-08 | 欧米茄治疗公司 | 用于调节肝细胞核因子4α(HNF4α)基因表达的组合物和方法 |
| GB2613225B (en) | 2020-03-04 | 2024-01-03 | Verve Therapeutics Inc | Compositions and methods for targeted RNA delivery |
| CA3173528A1 (en) | 2020-03-11 | 2021-09-16 | Omega Therapeutics, Inc. | Compositions and methods for modulating forkhead box p3 (foxp3) gene expression |
| US12194157B2 (en) | 2020-04-09 | 2025-01-14 | Finncure Oy | Carrier for targeted delivery to a host |
| FI20215508A1 (en) | 2020-04-09 | 2021-10-10 | Niemelae Erik Johan | Mimetic nanoparticles to prevent the spread of new coronaviruses and reduce the rate of infection |
| EP4228658A4 (en) | 2020-10-14 | 2025-02-19 | George Mason Research Foundation, Inc. | IONIZABLE LIPIDS AND METHODS FOR THE PRODUCTION AND USE THEREOF |
| WO2022099003A1 (en) | 2020-11-06 | 2022-05-12 | Sanofi | Lipid nanoparticles for delivering mrna vaccines |
| CN113509542A (zh) * | 2021-04-20 | 2021-10-19 | 嘉晨西海(杭州)生物技术有限公司 | 一种基于mRNA的表达白介素12针对肿瘤的药物及其制备方法 |
| EP4367242A2 (en) | 2021-07-07 | 2024-05-15 | Omega Therapeutics, Inc. | Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression |
| AU2022315530A1 (en) | 2021-07-20 | 2024-01-18 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their preparation, and uses |
| WO2023015223A2 (en) | 2021-08-03 | 2023-02-09 | Verve Therapeutics, Inc. | Compositions and methods for targeted rna delivery |
| CA3132191A1 (en) * | 2021-09-28 | 2023-03-28 | Providence Therapeutics Holdings Inc. | Compositions and methods for the prevention and/or treatment of covid-19 |
| KR20230053998A (ko) | 2021-10-15 | 2023-04-24 | (주)지노믹트리 | mRNA 발현을 위한 유전자 구조체 |
| MX2024005462A (es) * | 2021-11-05 | 2024-05-22 | Sanofi Sa | Vacuna de arn del virus respiratorio sincitial. |
| WO2023144127A1 (en) | 2022-01-31 | 2023-08-03 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their biodistribution upon administration, and uses |
| WO2023165582A1 (zh) * | 2022-03-04 | 2023-09-07 | 益杰立科(上海)生物科技有限公司 | 靶向递送系统和方法 |
| KR102796922B1 (ko) | 2022-04-11 | 2025-04-15 | 연세대학교 원주산학협력단 | mRNA 백신을 위한 양이온성 지질 나노입자 |
| WO2023232976A1 (en) | 2022-06-03 | 2023-12-07 | Ags Therapeutics Sas | Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses |
| JP2025523340A (ja) * | 2022-06-08 | 2025-07-23 | アカデミア シニカ | 脂質、それを含むナノ粒子およびその使用 |
| WO2024088808A1 (en) | 2022-10-24 | 2024-05-02 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof |
| EP4716741A2 (en) | 2023-05-23 | 2026-04-01 | Flagship Labs 114, Inc. | Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression |
| EP4722368A1 (en) | 2023-05-26 | 2026-04-08 | Samsung Biologics Co., Ltd. | Novel nucleic acid construct comprising poly(a) tail having secondary or tertiary structure and uses thereof |
| KR20250018367A (ko) | 2023-07-28 | 2025-02-05 | 한국과학기술원 | 히스톤 코드 리더 도메인을 포함하는 폴리펩티드 및 이의 용도 |
| WO2025144938A1 (en) | 2023-12-26 | 2025-07-03 | Emmune, Inc. | Systems for nucleic acid transfer |
| WO2025166325A1 (en) | 2024-02-02 | 2025-08-07 | Editas Medicine, Inc. | MODIFIED GUIDE RNAs |
| WO2025176843A1 (en) | 2024-02-21 | 2025-08-28 | Ags Therapeutics Sas | Microalgae extracellular vesicle based gene therapy vectors (mev-gtvs), their preparation, and uses thereof |
| WO2025210520A1 (en) * | 2024-04-04 | 2025-10-09 | Genevant Sciences Gmbh | Lipid nanoparticles for inducing an immunological response |
| WO2025213138A1 (en) | 2024-04-05 | 2025-10-09 | Editas Medicine, Inc. | Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma |
| CN119732909A (zh) * | 2024-12-24 | 2025-04-01 | 山东省药学科学院 | 一种具有促渗作用的纳米脂质体及其制备方法和应用 |
| CN121287885A (zh) * | 2025-12-11 | 2026-01-09 | 中国人民解放军军事科学院军事医学研究院 | 一种HGF mRNA脂质纳米颗粒（LNP）及其应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1519714B1 (en) | 2002-06-28 | 2010-10-20 | Protiva Biotherapeutics Inc. | Method and apparatus for producing liposomes |
| CA2532228C (en) | 2003-07-16 | 2017-02-14 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
| EP1664316B1 (en) | 2003-09-15 | 2012-08-29 | Protiva Biotherapeutics Inc. | Polyethyleneglycol-modified lipid compounds and uses thereof |
| CN101346393B (zh) | 2005-11-02 | 2015-07-22 | 普洛体维生物治疗公司 | 修饰的siRNA分子及其应用 |
| ES2535419T3 (es) | 2007-12-27 | 2015-05-11 | Protiva Biotherapeutics Inc. | Silenciamiento de expresión de quinasa tipo polo usando ARN interferente |
| CA2721333C (en) | 2008-04-15 | 2020-12-01 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for nucleic acid delivery |
| WO2011000107A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
| US9006417B2 (en) | 2010-06-30 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
| ES2557382T3 (es) | 2010-07-06 | 2016-01-25 | Glaxosmithkline Biologicals Sa | Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN |
| US8466122B2 (en) | 2010-09-17 | 2013-06-18 | Protiva Biotherapeutics, Inc. | Trialkyl cationic lipids and methods of use thereof |
| CA2811430A1 (en) * | 2010-09-30 | 2012-04-05 | Merck Sharp & Dohme Corp. | Low molecular weight cationic lipids for oligonucleotide delivery |
| EP3485913A1 (en) * | 2010-10-21 | 2019-05-22 | Sirna Therapeutics, Inc. | Low molecular weight cationic lipids for oligonucleotide delivery |
| EP2817287B1 (en) * | 2012-02-24 | 2018-10-03 | Arbutus Biopharma Corporation | Trialkyl cationic lipids and methods of use thereof |
| AU2013249548A1 (en) * | 2012-04-19 | 2014-11-06 | Sirna Therapeutics, Inc. | Novel diester and triester based low molecular weight, biodegradable cationic lipids for oligonucleotide delivery |
| JP6620093B2 (ja) | 2013-07-23 | 2019-12-11 | アービュートゥス バイオファーマ コーポレイションＡｒｂｕｔｕｓ Ｂｉｏｐｈａｒｍａ Ｃｏｒｐｏｒａｔｉｏｎ | メッセンジャーｒｎａを送達するための組成物及び方法 |
| EP3201338B1 (en) * | 2014-10-02 | 2021-11-03 | Arbutus Biopharma Corporation | Compositions and methods for silencing hepatitis b virus gene expression |
| JP2018509387A (ja) | 2015-01-21 | 2018-04-05 | フェーズアールエックス インコーポレイテッド | 細胞に治療および診断剤を送達するための方法、組成物、ならびにシステム |
| CN109563511A (zh) | 2016-06-30 | 2019-04-02 | 阿布特斯生物制药公司 | 用于递送信使rna的组合物和方法 |
| AU2017379901B2 (en) * | 2016-12-21 | 2024-02-15 | Arbutus Biopharma Corporation | Methods for ameliorating infusion reactions |
| CA3118559A1 (en) | 2018-11-09 | 2020-05-14 | Arbutus Biopharma Corporation | Lipid nanoparticle formulations |
-
2019
- 2019-11-08 KR KR1020217017641A patent/KR20210105889A/ko active Pending
- 2019-11-08 EA EA202191313A patent/EA202191313A1/ru unknown
- 2019-11-08 BR BR112021008982-9A patent/BR112021008982A2/pt unknown
- 2019-11-08 SG SG11202104807YA patent/SG11202104807YA/en unknown
- 2019-11-08 EP EP19880973.3A patent/EP3877521A4/en active Pending
- 2019-11-08 WO PCT/US2019/060582 patent/WO2020097540A1/en not_active Ceased
- 2019-11-08 US US17/291,942 patent/US12251470B2/en active Active
- 2019-11-08 JP JP2021525115A patent/JP2022506956A/ja active Pending
- 2019-11-08 UA UAA202103136A patent/UA130104C2/uk unknown
- 2019-11-08 CN CN201980088065.7A patent/CN113286882A/zh active Pending
- 2019-11-08 MX MX2021005389A patent/MX2021005389A/es unknown
- 2019-11-08 AU AU2019376161A patent/AU2019376161B2/en active Active
-
2021
- 2021-05-06 IL IL282995A patent/IL282995B1/en unknown
- 2021-05-12 ZA ZA2021/03233A patent/ZA202103233B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022506956A5 (enExample) | ||
| JP2022506955A5 (enExample) | ||
| JP7308000B2 (ja) | Ｖｅｇｆ－ａポリペプチドをコードする改変ｒｎａを送達するための脂質ナノ粒子 | |
| JP2022530018A5 (enExample) | ||
| KR102599712B1 (ko) | C/EBP 알파 saRNA 조성물 및 사용 방법 | |
| US20220226438A1 (en) | Compositions for skin and wounds and methods of use thereof | |
| JP6621409B2 (ja) | Ｃ／ＥＢＰα小分子活性化ＲＮＡ組成物 | |
| US20180258429A1 (en) | Sarna compositions and methods of use | |
| JP2022058438A (ja) | 親油性抗炎症剤を含む脂質ナノ粒子およびその使用方法 | |
| US20240018519A1 (en) | Stabilized saRNA Compositions and Methods of Use | |
| Huang et al. | An mTOR siRNA‐loaded spermidine/DNA tetrahedron nanoplatform with a synergistic anti‐inflammatory effect on acute lung injury | |
| US20230313191A1 (en) | Rna comprising secretomes and methods of their use | |
| WO2023051822A1 (zh) | 用于治疗与pcsk9相关疾病的靶向寡核苷酸 | |
| WO2024045251A1 (zh) | 一种治疗新生血管性视网膜疾病的小干扰rna及其dna四面体复合物 | |
| CN102784398B (zh) | 内皮抑素作为递送系统和化学合成的rna干扰分子组成的组合物及应用 | |
| ES2331835T3 (es) | Oligonucleotidos antisentido capaces de inhibir la formacion de tubos capilares. | |
| CN120754284A (zh) | 一种用于肝脏靶向联合递送CRISPR-Cas9系统和单链DNA修复模板的脂质纳米颗粒 | |
| TW202305133A (zh) | Tmem173 sarna組合物及其使用方法 | |
| US20240316165A1 (en) | Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia | |
| US20240269248A1 (en) | Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia | |
| WO2021115141A1 (zh) | 一种抑制HTT基因表达的siRNA及其前体和应用 | |
| CN104922698B (zh) | 人干细胞生长因子注射液及其制备方法 | |
| CN115998905B (zh) | 治疗心衰的mRNA药物制剂及其制备方法与应用 | |
| WO2020208361A1 (en) | Sirt1-sarna compositions and methods of use | |
| JP7525578B2 (ja) | Ｃ／ＥＢＰα小分子活性化ＲＮＡ組成物 |